Vancomycin
Brand names: Vancocin
Vancomycin is a glycopeptide antibiotic used intravenously for serious Gram-positive infections (including MRSA), and orally (where it is not absorbed) for Clostridioides difficile infection.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
US labelling (FDA)
Reference — US labelling, may differ from UKDOSAGE AND ADMINISTRATION Infusion-related events are related to both the concentration and the rate of administration of vancomycin. Concentrations of no more than 5 mg/mL and rates of no more than 10 mg/min, are recommended in adults (see also age-specific recommendations). In selected patients in need of fluid restriction, a concentration up to 10 mg/mL may be used; use of such higher concentrations may increase the risk of infusion-related events. An infusion rate of 10 mg/min or less is associated with fewer infusion-related events (see ADVERSE REACTIONS ). Infusion-related events may occur, however, at any rate or concentration. Patients with Normal Renal Function Adults The usual …
Source: US FDA prescribing information (openFDA / DailyMed), label dated 2026-01-30. Accessed 2026-06-12. US dosing and indications can differ from UK practice — use UK sources for prescribing decisions.
Clinical monograph
How it works
It inhibits bacterial cell-wall synthesis by binding peptidoglycan precursors; given orally it acts locally in the gut because it is not absorbed.
Prescribing in practice
- Intravenous dosing is guided by levels (trough or AUC) and renal function — it is nephrotoxic and ototoxic, especially with other such drugs.
- Rapid intravenous infusion causes the 'red man' (vancomycin infusion) reaction — infuse slowly.
- Oral vancomycin treats gut infection (C. difficile) only and does not treat systemic infection.
Monitoring
Monitor vancomycin levels and renal function during intravenous therapy; consider hearing where prolonged or with other ototoxic drugs.
Counselling the patient
- The intravenous form is given slowly to avoid flushing or rash.
- For C. difficile, the oral form works in the gut — complete the course.
- Attend blood tests to check levels and kidney function.
Evidence & guidelines
A mainstay for serious Gram-positive/MRSA infection (intravenous, level-guided) and a first-line oral treatment for C. difficile infection (NICE NG199).
Reference: ASHP/IDSA Vancomycin TDM Guidelines 2020; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Vancomycin Dosing Calculator · Drug Dosing
- Centor / McIsaac Score for Strep Pharyngitis · Throat
- FeverPAIN Score for Strep Throat · Throat
- Clostridioides difficile Severity Grading · Gastrointestinal Infection
- Jarisch-Herxheimer Reaction Severity Assessment · Treatment Reactions
- PID Severity (CDC Diagnostic Criteria) · Gynaecological Infections
- Major Trauma — Primary Survey (ATLS) · ATLS 10th Edition; JRCALC; NICE NG39
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Burns — TBSA Estimation & Fluid Resuscitation · British Burn Association; EMSB; RCEM 2024
- Lower Gastrointestinal Bleed · NICE; BSG; ACPGBI — Commissioning Guide
- Acute Pancreatitis · NICE; IAP/APA; ACPGBI — CG104
- Hypertrophic Pyloric Stenosis · BAPS / RCPCH